Pluto Bioinformatics

GSE128563: Genetic determinants of venetoclax resistance

Bulk RNA sequencing

Resistance to the first approved BCL-2 inhibitor venetoclax is emerging in lymphoid malignancies. The study aimed to identify the genetic determinants of such resistance. From genome-scale screens we determined the genes influencing the sensitivity to BCL-2 inhibition. The present set of data is related to expression changes (assessed by RNA sequencing) observed in the resistant OCI-Ly1 lymphoma cell line as well as those resulting from genetic perturbation (using CRISPR-Cas9) targeting the genes highlighted in our genome-scale screen. SOURCE: Candace Patterson ( - The Broad Institute

View this experiment on Pluto Bioinformatics